trial · primary record
ADG126
Advanced/Metastatic Solid Tumors
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 186 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab. |
| Registry ID | NCT05405595 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:54.741Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05405595
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.